Predictive biomarkers for response to trametinib in non-small cell lung cancer.
Palak R ParekhGregory M BottingDenise B ThurberMarika BoruszczakWilliam MurphyGreg P Bertenshaw
Published in: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine (2022)
Trametinib monotherapy outcome may depend upon cellular context more than oncogenic mutation status. In BRAF WT NSCLC, trametinib may be best suited for combination therapy and dynamic biomarkers could select combinations and predict responses.